Basic Information
| LncRNA/CircRNA Name | SLC6A9-5:2 |
| Synonyms | SLC6A9, GCENSG, GLYT1 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR, RNAi, Western blot, Luciferase reporter assay, Cell proliferation assay etc. |
| Sample | PTC tissues, cell lines (TPC-1 and BCPAP) |
| Expression Pattern | down-regulated |
| Function Description | We demonstrated that SLC6A9-5:2 was remarkably downregulated in 131I-resistant thyroid cancer cell lines and 131I-insensitive patients and was positively correlated with Poly (ADP-ribose) polymerase 1 (PARP-1) expression and its activation. After downregulating SLC6A9 or blocking PARP-1 artificially, the sensitive thyroid cancer cells mostly displayed a tolerant phenotype under 131I exposure. Furthermore, SLC6A9-5:2 overexpression was positively correlated with PARP-1 mRNA and protein levels, which restored the sensitivity of resistant thyroid cancer cells. |
| Pubmed ID | 28086241 |
| Year | 2017 |
| Title | LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. |
External Links
| Links for SLC6A9-5:2 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |